Sponsor of the Day:
Jerkmate
https://www.prnewswire.com/news-releases/neurocrine-to-acquire-soleno-therapeutics-expanding-its-endocrinology-and-rare-disease-portfolio-302734531.html
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
Apr 6, 2026 - VYKAT™ XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy...
soleno therapeuticsrare diseaseneurocrineacquireexpanding
https://www.statnews.com/2026/04/06/neurocrine-biosciences-soleno-therapeutics-acquisition-prader-willi-vykat/
Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal
Apr 6, 2026 - As part of the deal, Neurocrine will pick up an approved drug for the rare disease Prader-Willi syndrome, which has seen a successful launch.
neurocrine biosciencessoleno therapeutics2 9bbuydeal
https://soleno.life/
Soleno Therapeutics – Development and commercialization of novel therapeutics for the treatment of...
soleno therapeuticsdevelopmentcommercializationnoveltreatment
https://www.financialcontent.com/quote/NQ:SLNO
Soleno Therapeutics, Inc. - Common Stock (SLNO) Stock Price, News, Quote & History |...
The current price of Soleno Therapeutics, Inc. - Common Stock (SLNO) is 52.48 — it has gone up by +0.13 (0.25%) today. Soleno Therapeutics Inc is a...
therapeutics inc commonprice news quotesolenostockhistory